MedTrace Logo

Combination of Chemotherapy and Gefitinib as First-line Treatment

NCT02148380 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2016-04-20

No results posted yet for this study

Summary

The results of fastact2 show that chemotherapy plus erlotinib significantly prolonged PFS and OS of patients with NSCLC. However, outcome of the combination therapy are similar to those reported in several trials of single-agent EGFR TKIs. So which is the optimal first-line treatment for patients who harbored a sensitive EGFR mutation? The investigators need a head-to-head study to reply.

Conditions

  • Non-Small-Cell Lung Cancer

Interventions

DRUG

pemetrexed plus carboplatin

DRUG

gefitinib

Sponsors & Collaborators

  • Baohui Han

    lead OTHER

Principal Investigators

  • Baohui Han, Dr · Vice President of Shanghai Chest Hospital,Sponsor of study

  • Bo Jin, Dr · Study Leader,Doctor of Shanghai Chest Hospital

  • Yanjie Niu, Master · Doctor of Shanghai Chest Hospital

  • Yanwei Zhang, Dr · Doctor of Shanghai Chest Hospital

  • Tianqing Chu, Dr · Doctor of Shanghai Chest Hospital

  • Aiqin Gu, Master · Doctor of Shanghai Chest Hospital

  • Lei Zhu, Master · Doctor of Shanghai Chest Hospital

  • Jun Pei · Doctor of Shanghai Chest Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2014-12-31
Completion
2015-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02148380 on ClinicalTrials.gov